Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP613459.RAH5hoHD9BJgH75EM0honT1yZXQsc2n1iK5hGlGMw59NE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP613459.RAH5hoHD9BJgH75EM0honT1yZXQsc2n1iK5hGlGMw59NE130_assertion type Assertion NP613459.RAH5hoHD9BJgH75EM0honT1yZXQsc2n1iK5hGlGMw59NE130_head.
- NP613459.RAH5hoHD9BJgH75EM0honT1yZXQsc2n1iK5hGlGMw59NE130_assertion wasGeneratedBy ECO_0000203 NP613459.RAH5hoHD9BJgH75EM0honT1yZXQsc2n1iK5hGlGMw59NE130_provenance.
- NP613459.RAH5hoHD9BJgH75EM0honT1yZXQsc2n1iK5hGlGMw59NE130_assertion wasDerivedFrom befree-20150227 NP613459.RAH5hoHD9BJgH75EM0honT1yZXQsc2n1iK5hGlGMw59NE130_provenance.
- NP613459.RAH5hoHD9BJgH75EM0honT1yZXQsc2n1iK5hGlGMw59NE130_assertion SIO_000772 24342289 NP613459.RAH5hoHD9BJgH75EM0honT1yZXQsc2n1iK5hGlGMw59NE130_provenance.
- NP613459.RAH5hoHD9BJgH75EM0honT1yZXQsc2n1iK5hGlGMw59NE130_assertion evidence source_evidence_literature NP613459.RAH5hoHD9BJgH75EM0honT1yZXQsc2n1iK5hGlGMw59NE130_provenance.
- NP613459.RAH5hoHD9BJgH75EM0honT1yZXQsc2n1iK5hGlGMw59NE130_assertion description "[The final section will discuss the 4 most mature examples in the GI tract: (1) HER2 testing to select patients with advanced gastroesophageal adenocarcinoma for anti-HER2 therapy, (2) KIT and PDGFRA mutation analysis to direct tyrosine kinase inhibitor therapy in gastrointestinal stromal tumor, (3) DNA mismatch repair function testing to determine the applicability of adjuvant chemotherapy in patients with stage II colorectal cancer (CRC), and (4) KRAS mutation analysis and related testing to determine the appropriateness of anti-EGFR monoclonal antibody therapy in patients with metastatic CRC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP613459.RAH5hoHD9BJgH75EM0honT1yZXQsc2n1iK5hGlGMw59NE130_provenance.